Jones Financial Companies Lllp Grows Stock Position in Eli Lilly And Co (NYSE:LLY)

Share on StockTwits

Jones Financial Companies Lllp boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 9.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 7,211 shares of the company’s stock after buying an additional 606 shares during the period. Jones Financial Companies Lllp’s holdings in Eli Lilly And Co were worth $799,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in LLY. Wealthquest Corp lifted its position in shares of Eli Lilly And Co by 1.5% during the first quarter. Wealthquest Corp now owns 6,307 shares of the company’s stock worth $818,000 after purchasing an additional 94 shares during the last quarter. Lourd Capital LLC lifted its position in shares of Eli Lilly And Co by 2.7% during the second quarter. Lourd Capital LLC now owns 3,723 shares of the company’s stock worth $412,000 after purchasing an additional 97 shares during the last quarter. First Personal Financial Services lifted its position in shares of Eli Lilly And Co by 2.5% during the second quarter. First Personal Financial Services now owns 4,029 shares of the company’s stock worth $446,000 after purchasing an additional 98 shares during the last quarter. Meridian Wealth Advisors LLC lifted its position in shares of Eli Lilly And Co by 6.1% during the first quarter. Meridian Wealth Advisors LLC now owns 1,746 shares of the company’s stock worth $227,000 after purchasing an additional 100 shares during the last quarter. Finally, Webster Bank N. A. lifted its position in shares of Eli Lilly And Co by 5.6% during the second quarter. Webster Bank N. A. now owns 1,900 shares of the company’s stock worth $210,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 79.48% of the company’s stock.

In other Eli Lilly And Co news, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the transaction, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joshua L. Smiley bought 426 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was bought at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the purchase, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The disclosure for this purchase can be found here. 0.11% of the stock is owned by insiders.

LLY traded up $0.29 on Friday, hitting $110.52. The company had a trading volume of 3,423,700 shares, compared to its average volume of 4,237,085. The stock has a fifty day moving average price of $110.59 and a 200-day moving average price of $118.03. Eli Lilly And Co has a 12-month low of $103.65 and a 12-month high of $132.13. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13. The stock has a market capitalization of $106.42 billion, a price-to-earnings ratio of 19.91, a P/E/G ratio of 1.95 and a beta of 0.19.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm earned $1.48 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. Analysts forecast that Eli Lilly And Co will post 5.72 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $0.645 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.33%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

Several brokerages have recently commented on LLY. Cantor Fitzgerald restated a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a research note on Tuesday, April 30th. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, May 21st. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a research note on Tuesday, April 23rd. BMO Capital Markets raised their price target on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Finally, ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $123.49.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is meant by holder of record?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.